Skip to main content

Leuphasyl vs Dihexa

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Leuphasyl

Leuphasyl (Pentapeptide-18) is a cosmetic peptide that reduces muscle tension through a mechanism similar to enkephalins. Often combined with Syn-Ake for enhanced anti-wrinkle effects.

Full details →

Dihexa

Dihexa is a nootropic peptide derived from angiotensin IV. It has shown remarkable cognitive-enhancing properties in animal studies, being described as potentially millions of times more potent than BDNF.

Full details →

Side-by-Side Comparison

AspectLeuphasylDihexa
MechanismMimics enkephalin and binds to enkephalin receptors on muscle cells, reducing acetylcholine release and thereby decreasing muscle contraction intensity.Acts as a hepatocyte growth factor (HGF) potentiator by binding to its receptor c-Met. Promotes synaptogenesis, neuronal survival, and cognitive enhancement through this pathway.
Typical DosageTopical: 3-8% concentration in serums. Often used in combination products with other muscle-relaxing peptides.Research dosing is highly variable due to extreme potency. Typical range: 10-40mg orally or sublingually. Start with lowest doses due to potency.
AdministrationTopical application to expression lines. Best results with consistent twice-daily use over 8+ weeks.Can be taken orally, sublingually, or intranasally. Extremely potent - careful dosing is essential. Best used cyclically.
Side EffectsVery well-tolerated topically. No significant adverse effects reported at cosmetic concentrations.Limited human data. Reported effects include headache, temporary brain fog during adjustment, and potential mood changes.
Best For

Key Differences

Unique to Leuphasyl:

Unique to Dihexa:

Detailed Analysis

Dihexa and Leuphasyl are used for different purposes and have limited overlap in their applications.

Which Should You Choose?

Choose Dihexa for Cognitive Performance. Choose Leuphasyl for Skin Health & Aesthetics.

Ready to Learn More?